DIA Europe’s 2012 EuroMeeting in Copenhagen on Tuesday 27 March is the setting for the public launch of EUPATI – the European Patients’ Academy on Therapeutic Innovation. DIA Europe is a major partner in this IMI (Innovative Medicines Initiative) funded education programme that will significantly improve the European public’s understanding about the development of medicinal products.
The patient-led Academy aims to develop educational material, training courses and a public Internet library to educate patient representatives and the lay public about all processes involved in medicines development.
At a special launch press briefing on Tuesday 27 March, from 0900 -1030 at the Bella Center, Copenhagen, Jan Geissler, EUPATI Project Director, will present EUPATI and answer questions.
In the afternoon of Tuesday 27 March, Michel Goldman, Executive Director of the IMI, will open a special session at the Bella Center, Copenhagen, where the EUPATI consortium will present the project, explain the various work packages and collect the first feedback, ideas and thoughts from the public.
EUPATI is a unique and unprecedented collaboration between patient organisations representing the most frequent diseases, rare diseases, health professionals, academia, media, health-technology experts, multi-stakeholder non-profit organisations and the pharmaceutical industry. It is essentially a consortium, led by major pan-European umbrella patient advocacy groups, complemented by key academic players and non-profit organisations with a proven track record in generating patient education materials and tools – plus industry partners with a pan-European infrastructure and reach.
EUPATI aims to increase awareness of, understanding about and involvement in new treatment development processes and optimal treatment usage among European patients and the public at large. The Academy plans to build competencies among well informed patients and to establish a robust infrastructure for objective, credible, correct and up-to-date, on-going knowledge building for patient advocates and the broader patients' community, including hard to reach patients.
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.
Registration is required for entry to the press conference and the special session. For more information contact: Robin Gallon, Head of Communication, DIA Europe email@example.com.
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.
Contact: Robin Gallon
Phone: +41 61 225 51 47